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Abstract
Background: Familial combined hyperlipidaemia (FCH), characterized by elevated very-low-density lipoprotein (VLDL) 
and/or low-density lipoprotein (LDL), is associated with an increased prevalence of premature cardiovascular disease. 
Therefore, lipid-lowering is frequently indicated. Methods; We evaluated in a parallel, double-blind randomized fashion the 
effect of gemfibrozil (1200 mg/day) ( n =  40) or simvastatin (20 mg/day) (n — 41) on lipids, apolipoprotein-B (apo-B)-con- 
taining lipoproteins, apo-CIII and lipoprotein(a) [Lp(a)], in 81 well-defined FCH patients. Results: While both drugs lowered 
plasma cholesterol and triglyceride levels, gemfibrozil lowered plasma triglycerides more effectively by reduction of 
triglycerides in VLDL and LDL, whereas simvastatin was more effective in its reduction of total plasma cholesterol by 
exclusively decreasing LDL cholesterol. High-density lipoprotein (HDL) increased to an equal extent on both therapies. 
Total serum apo-B levels were reduced with both drugs; however, gemfibrozil decreased apo-B only in VLDL +  IDL, 
whereas simvastatin decreased apo-B in both VLDL -1- IDL and LDL. In keeping with a more effective reduction of VLDL 
particles, a more pronounced reduction of apo-CIII also was observed after gemfibrozil, which correlated with the reduction 
in plasma triglycerides. Baseline concentrations of Lp(a) showed a wide range in both treatment groups. Median Lp(a) levels 
increased after simvastatin, but were not affected by gemfibrozil. Conclusion: Both therapies exhibited their specific effects, 
although none of the drugs alone completely normalized the lipid profiles of these patients with FCH. Therefore, the choice 
of treatment should be based on the most elevated lipoprotein fraction, and in some cases a combination of the two drugs 
may be indicated.
Keywords: Lipids; Therapeutics; Clinical trial
1. Introduction
* Corresponding author. Tel. ( +  31-24) 3614782; fax: ( + 31-24)
3541734.
1 Part of this work was presented at the “Intemistendagen" Familial combined hyperlipidaemia (FCH) is the
Veidhoven, The Netherlands, 1995 (Neth J Med 1995;46:A68). most common of the hereditary lipid disorders, with
0300-2977/96/$ 15.00 Copyright © 1996 Elsevier Science B.V. All rights reserved 
PU S 0 3 0 0 - 2 9 7 7 ( 9 6 ) 0 0 0 1 5 -0
60 SJ.H . B redie el at. /  Netherlands Journal o f  Medicine 49(1996) 59-67
an estim ated prevalence of 0 .5 -1 .0%  in the general 
population and characterized by a strong predisposi­
tion to premature cardiovascular diseases in patients 
and first-degree relatives [1]. Affected individuals 
have elevated very-low-density lipoprotein (VLDL) 
concentrations, low-density lipoprotein (LDL) con­
centrations, or both. Furthermore, a low high-density 
lipoprotein (HDL) cholesterol concentration, an ele­
vated apolipoprotein-B (apo-B) concentration [2], and 
an increased prevalence o f atherogenic small dense 
LDL subfractions are observed [3-5]. Because o f the 
absence o f a specific clinical or metabolic marker for 
the disorder, and because o f characteristic variability 
in the presenting lipid phenotype, family investiga­
tion is pivotal to establish the diagnosis FCH in a 
single patient [2]. FC H  seems to be a metabolically 
and genetically heterogenous lipid disorder [6] which, 
in general, is explained by an overproduction of 
V LD L particles [7,8]. Furthermore, an impaired hy­
drolytic capacity o f lipoprotein lipase (LpL) itself 
[9], or elevated plasma levels of a  LpL inhibitor 
apo-CIII, possibly linked to genetic polymorphisms 
in the A I-CIII-A IV  gene cluster on chromosome 11 
[10,11], may be related to the FCH phenotypes.
In g e n e r a l ,  e le v a te d  c o n c e n t ra t io n s  o f  
lipoprotein(a) [Lp(a)] are related to an increased risk 
for cardiovascular disease, which is independent of 
the cardiovascular risk associated with elevated lipid 
levels [12]. A lthough FC H  is not associated with 
elevated Lp(a) levels [13], Lp(a) concentrations cor­
relate positively with LpL-mediated metabolism of 
triglyceride-rich lipoproteins [14]. Reduction of the 
elevated pool o f  triglyceride-rich lipoproteins, as seen 
in FCH, m ay influence plasm a Lp(a) levels [15].
Because o f  the high incidence o f cardiovascular 
diseases in these patients, lipid-lowering treatment 
should be initiated. If diet and lifestyle changes have 
insufficient effect, drug therapy may be indicated. 
For this purpose, the HM G-CoA reductase inhibitor, 
simvastatin, is highly effective in patients with pri­
mary hypercholesterolaemia [16], and fibrates like 
gemfibrozil with a  primary triglyceride-lowering ef­
fect [17] are useful.
To date, few comparative data are available on 
the different effects of these agents in FCH. In the 
present study we describe the baseline levels of 
lipids, apo-B-containing lipoproteins, apo-CIII and 
Lp(a) in well-defined patients with FCH, and com­
pare the results of treatment with either gemfibrozil 
or simvastatin on these parameters.
2. Materials and methods
2.7. Subjects
In total, 81 FCH probands from 3 centres partici­
pated in this study. A subgroup of this population 
has been studied regarding LDL subfraction profiles 
and LDL oxidizability [5]. In the present study the 
effects o f  treatment with either gemfibrozil or sim­
vastatin on serum lipids, lipoproteins, apo-CIII and 
Lp(a) in all 81 FCH probands are presented.
At the end of the screening period, all FCH 
patients met the following criteria: ( 1) a total serum 
cholesterol > 6 .5  mmol/1 and triglyceride level be­
tween 2.3 and 5.6 mmol/1, without hypolipidaemic 
drugs and on a standard lipid-lowering diet (30 
energy % fat, P / S  ratio of 2:1 and a cholesterol 
intake <  300 m g/day); (2) at least 1 first-degree 
relative with significant hypercholesterolaemia, hy- 
pertriglyceridaemia or both; (3) a positive family 
history of premature coronary heart disease; (4) total 
apo-B levels above 1200 m g/1. Furthermore, all 
patients were > 3 0  years old and patients with sec­
ondary causes for dyslipidaemia or with apolipopro- 
tein phenotype E 2 / 2  were excluded. The study 
protocol was approved by the local medical ethical 
committees, and all patients participated after in­
formed consent was obtained.
2.2. Experimental design
This study was a double-blind trial with a double 
dummy design, divided into a screening period 
(weeks — 8 to — 5), a baseline placebo period (weeks
— 4 to day 0) and an active treatment period (day 0 
to week 12). In the screening period, patients were 
taken off all hypolipidaemic drugs, receiving a stan­
dard lipid-lowering diet. When total plasma choles­
terol concentration exceeded 6.5 m m o l/ l ,  and plasma 
triglyceride concentration remained between 2.3 and 
5.6 m m o l/ l ,  the patients entered the baseline placebo 
period of the study. During this period, each patient 
received 2 bottles, one containing placebo matching 
gemfibrozil and one containing placebo matching
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simvastatin. During the active treatment period, pa­
tients were randomly assigned to receive either sim­
vastatin 20 m g /d a y  together with a placebo match­
ing gemfibrozil («  =  41) or gemfibrozil 1200 m g /  
day together with a placebo matching simvastatin 
(n =  4 0 ). In the present study we compared concen­
trations of total plasma cholesterol and plasma 
triglycerides obtained at the end of the entry period, 
at the end of the placebo period and at two time 
points (6 and 12 weeks) during the period of active 
treatment. Furthermore, analyses of lipoproteins, 
apoproteins and Lp(a) at the end of the placebo-con­
trolled period were compared with the same data at 
the end of the active treatment period.
2.3. Plasma
Blood samples were obtained after an overnight 
fast and collected in ethylenediaminetetraacetic acid 
(EDTA) (1 m g/m l)-contain ing vacutainers. Plasma 
was isolated immediately and a saccharose solution 
(600 m g /m l  H 20 )  was added to prevent dénatura­
tion of VLDL and LDL during freezing; samples 
were stored at — 80°C for 4 to 15 weeks. The 
analysis of apo-CIII and Lp(a) was performed in the 
Lipid Research Laboratory, University Hospital of 
Utrecht; apo-B was determined in the Lipid Research 
Laboratory, University Hospital of Amsterdam; all 
other lipid determinations were performed in the 
Lipid Research Laboratory, University Hospital of 
Nijmegen.
2.4. Analytical methods
Very-low-density lipoproteins (VLDL) and inter- 
mediate-density lipoproteins (IDL) were isolated to­
gether by ultracentrifugation at density <  1.019 
g/m l for 16 h at 40000  rpm in a fixed-angle rotor 
(TFT 45.6 rotor, Kontron, Zurich), in a Beckman 
L7-55 ultracentrifuge (Beckman, Palo Alto, USA)
[18]. After removal of VLDL +  IDL, we measured 
cholesterol and triglycerides in the remaining plasma 
and in total plasma. HDL was determined from 
whole plasma by the polyethylene glycol method
[19]. All cholesterol and triglyceride measurements 
were determined by enzymatic methods (Boerhringer 
Mannheim, Mannheim, Germany, cat. no. 237574 
and Sera Pak, Tournai, Belgium, cat. no. 6669,
respectively) with a centrifugal analyzer (M ultistat 
III; Instrumentation Laboratory, Lexington, MA). 
VLDL -h IDL cholesterol and triglyceride were cal­
culated by subtraction. Apo-B and apo-A I concentra­
tions in total plasma and apo-B concentrations in the 
fraction that remained after V L D L  +  ID L removal 
were determined by nephelometry [20]. V L D L  +  
IDL-apo-B was calculated by subtraction. Apo-CIII 
was determined quantitatively by radial im m unodif­
fusion using plates and apo-CIII standards, according 
to the manufacturer’s instructions (Daiichi Pure 
Chemicals, Ltd, Japan). The diam eter o f  the precip i­
tation ring was measured by an investigator unaware 
of the specimen’s identity. Serial sam ples from  each 
subject were measured in the sam e assay. Lp(a) 
concentrations were determined by m easuring  the 
apoprotein(a) moiety in a com m ercially  available 
solid-phase two-site im m u n o rad io m etr ic  assay  
(IRMA) using 2 different specific anti-apoprotein(a) 
monoclonal antibodies (Pharmacia, Uppsala, S w e­
den).
2.5. Statistics
Results are expressed as m ean ±  SD  and as m e­
dian for Lp(a). Statistical analysis o f  alterations 
within one group of treatment was perform ed with 
W ilcoxon’s Signed R ank test. D ifferences in terms 
of percentage between the two groups o f treatment 
were analyzed with the M ann-W hitney test. A two- 
tailed probability value o f less than 0.05 was consid­
ered to be significant. The statistical analysis were 
performed with procedures available in the SPSS 
PC 4- (Statistical Package for the Social Sciences) 
software package Version 4.0 (SPSS Inc. Chicago, 
IL, USA)
3. Results
3.1. Participants
After the screening period (4 weeks), participants 
who exhibited a lib phenotype (total p lasm a choles­
terol concentration >  6.5 m m o l/1  and plasm a 
triglyceride concentration > 2 . 3  m m o l / l )  were al­
lowed to enter the placebo period. Due to variability 
in presenting lipid phenotype during the placebo
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Fig. I. Change in plasma concentrations (mmol/1) of total cholesterol (TC) and triglycerides (TG) during the placebo period (week - 4  to 
day 0), and at two time-points (week 6 and week 12) during the period of active treatment with either gemfibrozil ( □ )  (ft = 40) or 
simvastatin ( ■ )  (n  =  41) of patients with familial combined hypcrlipidaemia. * P <  0.001, * * P <0.0001, compared with the baseline 
level (week 0).
period (4 weeks), 55 patients exhibited a phenotype 
lib , 12 patients exhibited a phenotype Ha (total 
plasma cholesterol concentration > 6 .5  and plasma 
triglyceride concentrations < 2 .3  mmol/1), and 14 
patients exhibited a phenotype IV (total plasma 
cholesterol concentration <  6.5 m m ol/1  and plasma 
triglyceride concentration >  2.3 mmol/1, respec­
tively) at the end o f the baseline placebo period. 
Description o f the two treatment groups, the body
mass index (BMI), and the blood pressure are pre­
sented in Table 1.
3.2. Effect o f treatment on lipid and lipoprotein 
concentrations
In Fig. 1 the changes in the mean total plasma 
cholesterol and plasma triglyceride concentrations 
during the placebo period and the period of treatment
Table 2
Lipid and lipoprotein concentrations at the end of the placebo period ( -  before) and after treatment ( -  after) with either gemfibrozil 
(rc =  40) or simvastatin (n =  41) of patients with familial combined hypcrlipidaemia
Drug Before After Delta (%) P
TC G 7.50 ± 0 .98 6.73 ±  0.91 - 9 .5  ±  13.2 0.0001
S 7.30 ± 0 .9 6 5.67 ±  1.00 -2 2 .4  ± 9 .2  aa < 0.0001
TG G 3.22 ±  1.22 1.64 ±0.59 -4 5 .5  ±  19.7 < 0.0001
S 3.20+  1.20 2.63 ±0.88 -1 4 .6  ± 27 .8  aa 0.0003
HDL-C G 0.91 ± 0 .2 0 1.07 ±  0.26 17.4 ±  17.6 < 0.0001
S 0.84 ± 0 .1 9 0.95 ±0.21 13.9 ±  13.1 < 0.0001
VLDL 4- IDL-C G 2.43 ±  0.84 1.15 ±0 .84 -5 0 .6  ± 20 .6 < 0.0001
S 2.60 ±  1.02 1.56 ±  0.62 — 37.6 ±  20.1 aa < 0.0001
VLDL +  IDL-TG G 2.61 ±  1.18 1.43 ±  1.15 ”  44.7 ±  28.0 < 0.0001
S 2.59 ± 1.04 2.08 ±  0.79 — 14.1 ±  32.6 aa 0.0008
LDL-C G 4.08 ±  0.99 4.29 ±  1.26 8.3 +  41.9 n.s.
S 3.87 ± 0 .98 3.16 ±0.87 -1 6 .3  ± 2 1 .0  aa < 0.0001
LDL-TG G 0.67 ±  0.20 0.49 ±0.13 -2 2 .9  ±  19.9 < 0.0001
S 0.60 ± 0.12 0.53 ±0 .12 — 10.9 ±  16.8 a 0.0003
Values are presented in mmol/1 as mean ±  SD. TC =  total plasma cholesterol; TG =  plasma triglycerides; VLDL =  very-low-density 
lipoproteins; IDL =  intermediate-density lipoproteins; IIDL =  high-density lipoproteins; LDL =  low-density lipoproteins; G = 
gemfibrozil, S -  simvastatin; n.s., not significant.11 P < 0.001, aa P < 0.0001, S versus G.
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Table 1
Age, gender, blood pressure and body mass index of 81 patients 
with familial combined hyperlipidaemia
3.3. Effect o f treatment on apo-B-containing iipopro-
Gemfibrozil Simvastatin
n
Age (years)
Gender M /F
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Body mass index (k g /m 2)
40
53.4 +  9.4 
2 6 /1 4  
131 ±  18 
84 +  9 
27.2 +  3.0
41
50.4 +  10.8 
3 2 /9  
127 ±  13 
81 ±  8 
26,6 + 2.7
Values are presented as mean +  SD.
are presented. At entry and at the end of the placebo 
period there were no significant differences in mean 
lipid and lipoprotein concentrations between the two 
groups, and as shown in Fig. 1, mean lipid levels 
were unaffected during the placebo period. Lipopro­
tein levels at the end of the baseline period and after 
therapy are summarized in Table 2. During the treat­
ment period, the BMI appeared to be constant in 
both groups. Gemfibrozil affected total triglyceride 
levels in plasma as well as in the VLDL + IDL and 
LDL fraction significantly more than simvastatin, 
whereas simvastatin induced the largest reduction in 
total plasma cholesterol with an exclusive reduction 
of LDL-cholesterol. Gemfibrozil tended to increase 
LDL-cholesterol ( + 8.3%, not significant). In both 
groups, the reduction of cholesterol and triglycerides 
in the VLDL + IDL fraction was responsible for the 
major decrease on total plasma cholesterol and 
triglycerides. With both drugs, HDL-cholesterol con­
centrations increased significantly to an equal extent.
teins
Alterations in the apo-B concentrations in total 
plasma, the VLDL + IDL fraction and the LDL frac­
tion are presented in Fig. 2. Simvastatin and gemfi­
brozil reduced total plasma apo-B ( — 25.6 and
— 13.7%, respectively, but simvastatin was more 
effective if measured in percentage of change, P =  
0.02). Simvastatin reduced apo-B in both the VLDL 
+ IDL and the LDL fraction (-3 5 .4  and 16.7%, 
respectively). Gemfibrozil, on the contrary, reduced 
apo-B only in the VLDL + IDL fraction ( — 42.4%; 
difference simvastatin vs. gemfibrozil in terms of 
percentage change, P <0.0001), without affecting 
the LDL fraction ( + 5.5%, not significant; difference 
simvastatin vs. gemfibrozil in terms of percentage 
P <  0 .0001).
3.4. Effect o f treatment on apo-AI and apo-CIII
Changes in apo-AI and apo-CIII are summarized 
in Table 3. The increase in HDL-cholesterol on both 
treatments was not accompanied by an increase of 
apo-AI in both groups. Apo-CIII decreased signifi­
cantly with both therapies, but more markedly after 
gemfibrozil. In general, the absolute decrease in 
Apo-CIII concentrations coincided with the decrease 
in VLDL + IDL particles, as measured by apo-B 
concentrations in this fraction. There was a signifi­
cant correlation between the changes in apo-CIII and 
the change in plasma triglycerides after gemfibrozil
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Fig. 2. Effect of tteatment with either gemfibrozil (n =  40, left) or simvastatin (n ~  41, right) on apolipoprotein-B-containing lipoproteins in 
total plasma, the LDL fraction and the VLDL +  IDL fraction of patients with familial combined hyperlipidaemia, before (solid columns) 
and after (hatched columns) treatment. * P — 0.001, P =  0.0001.
64 S.J'H . B redie et a i /  Netherlands Journal o f  Medicine 49 (1996) 59-67
Table 3
Lipoprotein (a) [Lp(a)]. apolipopmtein-AI (apo-AI) and 
apolipoprotein-CIII (apo-CIII) at the end of the placebo period 
( =  before) and after treatment ( — after) with either gemfibrozil 
(> j -4 0 )  or simvastatin (/i =  41) of patients with familial com­
bined hyperlipidaemia
Drug Before After Delta (%) P
Lp(a) G 18.0 20.7 10.2 ±38.9 n.s.
S 19.6 26.1 14.9 ±31.1 0.015
A p oA  I G 131.5 +  24.7 134.4 ±24.1 2 .9+12.2 NS
S 136.7+25.4 133.7 +  22.2 - 0.1 ±18.1 NS
Apo-CIII G 14.8 ± 3 .4 10.6 +  2.3 -2 6 .0  ±17.2 < 0.0001
s 14.7 ± 4 .7 13.6 +  3.6 - 6 .4  +  20.3 a 0.005
Values are presented in m g/dl as median for Lp(a) and as 
mean + SD for apo-AI and apo-CIII. S = simvastatin; G =  
gemfibrozil; n.s. =  not significant. A P <  0,0001, S versus G.
and simvastatin ( r  —0.69 and r  =  0.67; P — 0.001, 
respectively).
3.5. Effect o f  treatment on Lp(a)
Before and after therapy Lp(a) values showed a 
wide distribution. Effects on median levels are sum­
marized in Table 3. The effect of gemfibrozil was 
not significant, 18 out o f 40 patients showed a 
decrease, but conversely, 27 out of 41 patients 
showed an increase in Lp(a) levels on simvastatin,
4. Discussion
In spite o f  often mildly elevated lipid levels com­
pared to other lipid disorders, there is a high preva­
lence of cardiovascular diseases in FCH families. 
Consequently, family screening and pharmacological 
intervention in affected individuals may be indicated 
[21]. The increased tendency to premature cardiovas­
cular disease in these patients must be related to the 
increased pool o f  triglyceride-rich apo-B-containing 
lipoproteins in conjunction with elevated LDL- 
cholesterol levels [22,23]. In addition, hypertriglyc- 
eridaemia, as found in FC H  with type lib and IV 
phenotypes, is associated with augmented exchange 
o f lipids between VLDL, H D L and LDL, mediated 
by cholesteryl transfer protein (CETP), which may 
result in more small dense atherogenic LD L particles 
in total LD L [24,25]. Elevated apo-CIII concentra­
tions may be associated with hypertriglyceridaemia, 
because of a possible inhibition of LpL activity by 
apo-CIII [26]. Furthermore, decreased HDL- 
cholesterol, apo-AI concentrations and elevated con­
centrations of Lp(a) may also be involved in the 
atherogenesis in FCH [13,27].
Recently, large prevention trials and studies with 
solid cardiovascular end-points have now established 
that cholesterol-lowering results in a decrease in 
mortality from cardiovascular disease, and regression 
of atherosclerotic lesions [28-31 ]. Although the study 
populations did not meet the FCH diagnostic criteria, 
it can be deduced from these results that lipid-lower­
ing may affect mortality and morbidity from cardio­
vascular events in FCH patients as well, because 
lipid parameters associated with an increase in car­
diovascular risk were also influenced in the present 
study.
The observed reduction of total plasma choles­
terol and plasma triglyceride concentrations with 
simvastatin ( — 22.4 and —9.5%, respectively) and 
gemfibrozil ( — 14,6 and —45.5%, respectively) after 
12 weeks of treatment in our study are in accordance 
with previous reports [32,33]. To investigate the 
effect of both therapies on triglyceride-rich apo-B- 
containing lipoproteins, VLDL and IDL particles 
were isolated together. This explains the relatively 
large contribution of VLDL +  IDL-cholesterol and 
the relatively small contribution of LDL-cholesterol 
to total plasma cholesterol, both before and after 
treatment. The increase in HDL-cholesterol with 
gemfibrozil therapy agrees with previous studies as 
well [32,34], but the increase in HDL on simvastatin, 
despite a less pronounced reduction of triglycerides, 
is larger than previously reported [32]. The mean 
apo-AI concentration was unaffected, despite an in­
crease in HDL-cholesterol and may reflect HDL- 
cholesterol particles containing less protein [35]. The 
effects on LDL-cholesterol are comparable with other 
reports [32,33]. The depletion of triglycerides in the 
VLDL +  IDL fraction, leading to more small dense 
particles, which are more likely to be converted into 
LDL particles, is suggested to be a cause of the 
observed increase in LDL-cholesterol after gemfi­
brozil [36]. On the other hand, a triglyceride reduc­
tion in the LDL particle, more pronounced after 
gemfibrozil, yields more buoyant LDL subfractions, 
as we have demonstrated before [5,37]. These buoy­
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ant LDL subfractions may be less atherogenic be­
cause an increased resistance against oxidative modi­
fication has been described [18]. We observed that 
simvastatin most effectively reduced the total LDL- 
choleslerol concentration, but did not affect the LDL 
subfraction profile of FCH patients [5], which was 
recently demonstrated for pravastatin as well [38].
All patients had moderate to severe elevations of 
apo-B levels. Both therapies reduced total apo-B, but 
in accordance with the reduction of total apo-B-con- 
taining particles, simvastatin reduced apo-B in both 
the VLDL IDL and LDL fraction more effectively 
than gemfibrozil, which only reduced VLDL +  IDL- 
apo-B. Since VLDL +  IDL and LDL particles con­
tain only one molecule of apo-B per particle, a 
reduction of apo-B observed in these fractions re­
flects a reduction of the number of potential athero­
genic particles per isolated fraction.
It has been suggested that an elevated apo-CIII 
concentration may be a metabolic marker for FCH. 
The decrease in the apo-CIII concentrations in this 
study, however, significantly correlated with the de­
crease in triglyceride-rich lipoproteins and paral­
lelled the reduction of the particle numbers in the 
VLDL -h IDL fraction. Recently, Patsch et aL found 
a lower apo-CII/apo-CIII ratio, due to an elevated 
apo-CIII concentration, in VLDL particles of patients 
with type lib  hyperlipidaemia, which was related to 
sequence variations in the minor allele of the 
A I /C I I I /A I V  gene cluster on chromosome 11 [39], 
From our results, it remains to be seen whether 
increased apo-CIII concentrations have some role in 
the pathophysiology of FCH and can serve as a 
metabolic marker.
So far, the effects of hypolipidaemic drugs on 
Lp(a) levels have not been very successful. Studies 
with simvastatin demonstrated either no effect [40] 
or an increase in Lp(a) concentrations [15], Although 
it has been shown that Lp(a) may be bound to 
triglyceride-rich lipoproteins [41] and that LpL-medi- 
ated clearance of triglyceride-rich lipoproteins influ­
ences Lp(a) concentrations [14], the mechanism be­
hind this association remains unclear. Synthesis of 
Lp(a) in the liver may share some characteristics 
with VLDL synthesis, which is dependent on the 
amount of free fatty acids to the liver cell [42]. It is 
still unclear which causes underlie this possible in­
creased supply of free fatty acids to the liver cell in
FCH. Gemfibrozil, however, which m ay have some 
effect on the release o f  fatty acids from adipose 
tissue, had no significant effect on Lp(a) concentra­
tions.
In conclusion, we directly com pared the effects of 
two drugs with different working m echanisms in a 
well-defined large group of FC H  patients in order to 
support the choice o f treatm ent for this heteroge­
neous lipid disorder. None o f  these agents com­
pletely normalized the lipid and lipoprotein profiles. 
However, each agent has its specific effect in the 
treatment of subjects w ith  both elevated total plasma 
cholesterol and triglyceride concentrations. The use 
of drugs should be based on which lipoprotein frac­
tion is elevated the m ost during several visits to the 
out-patient clinic, and probably a  combination of 
gemfibrozil and simvastatin m ay be the therapy of 
choice in selected FCH patients with a high risk of 
cardiovascular disease.
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